• REsect is a retrospective analysis of the SIRFLOX study patient cohort.
  • The extensive radiological database of SIRFLOX was evaluated by a panel of 14 HPB (Hepato-Pancreato-Biliary) surgeons from leading medical centres in Belgium, France, Germany, Italy, The Netherlands, Spain, the UK and the USA to compare potential liver resectability at baseline and follow-up.

Key Findings

The addition of a single session of SIR-Spheres Y-90 resin microspheres to FOLFOX (± bev)-based chemotherapy significantly increased by 9.2% the number of patients deemed technically resectable compared with chemo alone (38.1% in the SIRT + chemotherapy arm vs. 28.9% in the chemotherapy alone arm; p<0.0001).

Study Overview

  • Analyses of baseline and follow-up scans from 472 patients.
  • The reviewers were blinded to patient identifiers, visit (baseline or follow-up), treatment and clinical information, as well as to the other reviewers’ assessments.
  • A patient was deemed resectable or unresectable by majority agreement (≥3 of 5 surgeons or ≥2 of 3 surgeons).

Patient characteristics

A total of 472 patients with similar baseline characteristics were evaluable (mFOLFOX n=228; mFOLFOX + SIRT n = 244).

resectpatientcharacteristics

Eligibility for Resection

REsect showed increased eligibility for liver resection following SIR-Spheres Y-90 resin microspheres.

resect-eligibility-for-resection

  • In patients with miliary disease* 3% in the control arm and 13% in the SIRT arm were considered to have resectable lesions at follow-up (p=0.029)
  • Significantly more patients with an initial hepatic tumour burden ≤ 25% had technically resectable liver metastases at follow-up in the SIRT arm than those in the control arm (49.4% vs 34.7%, p=0.008)

*Miliary disease was defined as at least 15 metastases, with reason to assume the patient would remain unresectable after treatment

bev: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)

Publication now online Garlipp B et al. Br J Surg 2019 Aug ePub: doi: 10.1002/bjs.11283.

 


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×